---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: ADX-324-302"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: ADX-324-302. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 17 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence/adx-324-302"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: ADX-324-302

<a id="heading-3.1.3"></a>

## 3.1.3 ADX-324-302

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Registry brief summary

> “Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial.”
> “The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE).”
> “The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Registry dates and number of locations

> “Study Start (Actual) 2026-04-02 Primary Completion (Estimated) 2030-06-30 Study Completion (Estimated) 2030-06-30”
> “This study has 48 locations”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="topic-3.1.3.2-2"></a>

#### UK research ethics committee opinion

| Field | Reported value |
| --- | --- |
| REC reference | “26/SC/0102” |
| Date of REC opinion | “12 May 2026” |
| REC opinion | “Further Information Favourable Opinion” |

Source: [Health Research Authority (2026)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/extension-study-of-adx-324-in-hae/)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Registry design details

| Field | Reported value |
| --- | --- |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Double” |

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="topic-3.1.3.3-2"></a>

#### Treatment duration and maintenance of the core-study blind

> “All eligible participants in the main study will be enrolled on the extension study and administered ADX-324 for up to 3 years.”
> “In order to maintain the blind in the core study, all participants will receive an injection Q3M; participants in the Q6M regimen will alternate between ADX-324 and placebo Q3M while participants in the Q3M group will receive ADX-324 Q3M as outlined.”

Source: [Health Research Authority (2026)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/extension-study-of-adx-324-in-hae/)

<a id="topic-3.1.3.3-3"></a>

#### Sponsor description of the extension

> “A long-term extension clinical trial will further evaluate open-label onvuzosiran treatment for up to three years, with, after 6 months, all participants (including placebo patients from STOP-HAE) moved onto active drug in the open label long term follow up.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.3.3-4"></a>

#### Attack recording during the extension

> “The eDiary will be used to continue to track your HAE attacks throughout the extension study.”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Registry inclusion and exclusion criteria

> “Have a documented diagnosis of HAE (Type I or II)”
> “Completed Study ADX-324-301”
> “Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)”
> “A negative reaction to study drug in ADX-324-301”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="topic-3.1.3.4-2"></a>

#### Eligibility assessment at the end of the core study

> “participants will be assessed for study eligibility for this extension study.”

Source: [Health Research Authority (2026)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/extension-study-of-adx-324-in-hae/)

<a id="topic-3.1.3.4-3"></a>

#### Early withdrawal from the core study

> “Should you end participation early in the primary study, you will not be eligible to participate in the extension study.”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Regimens by core-study assignment

> “Participants who received ADX-324 in the core study will continue to receive the same dosing regimen as in the core study (ie, ADX-324 300 mg every 6 months [Q6M] in Group 1 or 240 mg every 3 months [Q3M] in Group 2).”
> “Participants who received placebo 1.5 mL in the core study will receive ADX-324 300 mg Q6M (Group 1) and those who received placebo 1.2 mL in the core study will receive 240 mg Q3M (Group 2).”

Source: [Health Research Authority (2026)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/extension-study-of-adx-324-in-hae/)

<a id="topic-3.1.3.5-2"></a>

#### Registry interventions

| Intervention | Reported description |
| --- | --- |
| ADX-324 Dose Level 1 | “siRNA duplex oligonucleotide” |
| ADX-324 Dose Level 2 | “siRNA duplex oligonucleotide” |

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="topic-3.1.3.5-3"></a>

#### Study drug cost to participants

> “All participants will receive ADX-324 at no cost.”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Primary endpoint: registry definition

> “Incidence and severity of treatment-emergent adverse events”
> “Month 36”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="topic-3.1.3.6.1-2"></a>

##### Secondary endpoint: registry definition

> “Number of Investigator-confirmed HAE attacks per month”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Registry planned enrollment

> “Enrollment (Estimated) 90”

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499)

<a id="topic-3.1.3.7.1-2"></a>

##### Participants analyzed

No evidence found.

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

No evidence found.

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary

No results are available. The extension began in April 2026 and has an estimated primary completion date of June 2030. Allocation is non-randomized and every participant receives onvuzosiran, so the extension has no concurrent control group for safety or attack-rate comparisons. The core-study assignment remains masked through alternating onvuzosiran and placebo injections in the every-6-months group; the extension itself is not blinded to active treatment. Enrollment is limited to participants who completed STOP-HAE, and participants with a negative reaction to study drug in STOP-HAE are excluded, so the extension population may under-represent participants who did not tolerate or did not continue onvuzosiran. The primary endpoint is the incidence and severity of treatment-emergent adverse events through Month 36, and the monthly attack rate is a secondary endpoint. Planned enrollment is approximately 90 participants, which limits the detection of uncommon adverse events. No statistical analysis plan or analysis population definitions have been published.

Source: [ClinicalTrials.gov NCT07428499](https://clinicaltrials.gov/study/NCT07428499); [Health Research Authority (2026)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/extension-study-of-adx-324-in-hae/); [ADARx Pharmaceuticals](https://stophae.com/)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
